abemaciclib

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

abemaciclib

NCI Definition [1]:

An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Biomarker-Directed Therapies

Abemaciclib can be used in the treatment of breast carcinoma. ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for use of abemaciclib [2].

Breast Carcinoma +

Disease is predicted to be sensitive to abemaciclib: -

Biomarker Criteria:

Sample must match all of the following:

HER2 Negative Alteration Group

Sample must match all of the following:

Hormone Receptor Positive

Clinical Setting(s): Metastatic (FDA, NCCN)

Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Biomarker Criteria: Sample must match all of the following: Sample must match all of the following: HER2 Negative Alteration Group Sample must match all of the following: Hormone Receptor Positive	Clinical Setting(s): Metastatic (FDA, NCCN)
	Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Clinical Trials

View Clinical Trials for abemaciclib

Abemaciclib has been investigated in 101 clinical trials, of which 86 are open and 15 are closed. Of the trials investigating abemaciclib, 7 are early phase 1 (5 open), 21 are phase 1 (19 open), 13 are phase 1/phase 2 (10 open), 50 are phase 2 (44 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (7 open), and 2 are phase 4 (0 open).

ER Positive, ER Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for abemaciclib clinical trials.

Breast carcinoma, malignant solid tumor, and invasive breast carcinoma are the most common diseases being investigated in abemaciclib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Abemaciclib

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Abemaciclib

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating abemaciclib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

ly2835219, ly-2835219, 2-pyrimidinamine, n-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1h-benzimidazol-6-yl), abemaciclib, 2-pyrimidinamine, n-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1h-benzimidazol-6-yl), 1231929-97-7, cdk4/6 dual inhibitor ly2835219

Drug Categories [2]:

CDK inhibitors, CDK4/6 inhibitors, Serine/threonine kinase inhibitors

Drug Target(s) [2]:

CDK4, CDK6

NCIT ID [1]:

C97660

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /